Literature DB >> 2564901

Natural history of localised prostatic cancer. A population-based study in 223 untreated patients.

J E Johansson1, H O Adami, S O Andersson, R Bergström, U B Krusemo, W Kraaz.   

Abstract

In a population-based study, disease progression and survival were evaluated in untreated patients with newly diagnosed cancer of the prostate without distant metastases. Complete follow-up was achieved in 223 of 227 (98%) consecutively diagnosed, eligible patients of all ages. After 5 years, the cumulative progression-free survival (with 95% confidence interval) was 71.8 (65.5-78.1)% and survival corrected for causes of death other than prostatic cancer was 93.8 (88.3-97.6)%. Univariate and multivariate analyses showed no association between age at diagnosis and the natural course. Local progression was less common in localised, non-palpable tumours than in larger tumours. The rate of progression was 18.7 (6.1-57.1) times higher and that of disease-specific death 216.0 (31.2-1496) times higher in patients with poorly than in those with highly differentiated tumours. It is concluded that tumour grade at diagnosis is an excellent predictor of local and distant progression. The low death rate, especially in patients with highly and moderately differentiated tumours, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.

Entities:  

Mesh:

Year:  1989        PMID: 2564901     DOI: 10.1016/s0140-6736(89)92269-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  Localised carcinoma of the prostate: a paradigm of uncertainty.

Authors:  S S Sandhu; A V Kaisary
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

Review 2.  Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits.

Authors:  K G Marshall
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

Review 3.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  Carcinoma of the prostate--state at initial presentation.

Authors:  V Srinivas; H Mehta; A Amin; R Choudary; N Gadgil; D Ravishanker; A G Phadke
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

5.  Screening for prostatic cancer.

Authors:  R H Harwood
Journal:  BMJ       Date:  1993-03-27

6.  What is the risk posed by prostate cancer?

Authors:  Peter C Albertsen
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

7.  Expectant management as an option for men with stage T1c prostate cancer: a preliminary study.

Authors:  J L Mohler; B T Williams; J A Freeman
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

8.  Screening for prostate cancer. How can patients give informed consent?

Authors:  K G Marshall
Journal:  Can Fam Physician       Date:  1993-11       Impact factor: 3.275

9.  Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience.

Authors:  C Münger-Beyeler; J Bernhard; K Rufibach; R Morant; H-P Schmid
Journal:  Support Care Cancer       Date:  2007-10-02       Impact factor: 3.603

10.  Multiple transrectal ultrasound-guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion.

Authors:  M Norberg; L Holmberg; C Busch; M Häggman; L Egevad; A Magnusson
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.